Corcept Therapeutics Incorporated (NASDAQ:CORT) is a top future stock according to analysts. On August 14, analyst Edward Nash maintained a Buy rating and $137.00 price target, citing promising developments like the novel glucocorticoid modulator, relacorilant, and NDA submissions for Cushing’s syndrome and ovarian cancer treatment.

Corcept Therapeutics’ relacorilant shows progress in regulatory and clinical areas. The FDA has accepted NDA submissions for Cushing’s syndrome and ovarian cancer treatments, with a decision expected by the end of 2025. Analysts foresee a potential launch of the ovarian cancer treatment by mid-2026, boosting the company’s outlook.

Corcept Therapeutics (NASDAQ:CORT) is a biopharmaceutical company focusing on therapies that adjust cortisol effects. Its FDA-approved product, Korlym, treats Cushing’s syndrome. While CORT’s potential as an investment is recognized, other AI stocks may offer greater upside potential with less downside risk, according to analysts.

Analysts are optimistic about Corcept Therapeutics’ (NASDAQ:CORT) future due to advancements in its glucocorticoid modulator and NDA submissions for treating Cushing’s syndrome and ovarian cancer. The company’s focus on cortisol regulation and promising therapies support its positive outlook in the biopharmaceutical industry.

Read more at Yahoo Finance.: Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT